| 臺大學術典藏 |
2020-08-12T08:25:31Z |
First- or second-line therapy with gefitinib produces equal survival in non-small cell lung cancer
|
Wu J.-Y.; Yu C.-J.; Yang C.-H.; SHANG-GIN WU; Chiu Y.-H.; Gow C.-H.; Chang Y.-C.; Hsu Y.-C.; Wei P.-F.; Shih J.-Y.; Yang P.-C. |
| 臺大學術典藏 |
2022-06-27T07:07:54Z |
First- or second-line therapy with gefitinib produces equal survival in non-small cell lung cancer
|
Wu J.-Y.; CHONG-JEN YU; Yang C.-H.; Wu S.-G.; Chiu Y.-H.; Gow C.-H.; Chang Y.-C.; Hsu Y.-C.; Wei P.-F.; Shih J.-Y.; Yang P.-C. |
| 國立臺灣大學 |
2008-10 |
First- or second-line therapy with gefitinib produces equal survival in non-small cell lung cancer.
|
Wu, Jenn-Yu; Yu, Chong-Jen; Chih-HsinYang; Wu, Shang-Gin; Chiu, Yueh-Hsia; Gow, Chien-Hung; Chang, Yeun-Chung; Hsu, Ya-Chieh; Wei, Pin-Fei; Shih, Jin-Yuan; Yang, Pan-Chyr |
| 慈濟大學 |
2012 |
First-attack pediatric hypertensive crisis presenting to the pediatric emergency department
|
Yang, Wen-Chieh;Zhao, Lu-Lu;Chen, Chun-Yu;Wu, Yung-Kang;Chang, Yu-Jun;Wu, Han-Ping |
| 淡江大學 |
2007-03 |
First-Best Tax Policy, Congestion, and Imperfect Competition
|
Hung, Hsiao-wen |
| 中原大學 |
2001 |
First-come-First-Served Polling Systems
|
Kuo-Hwa Chang |
| 國立交通大學 |
2019-04-03T06:40:15Z |
First-ever ischemic stroke in elderly patients: predictors of functional outcome following carotid artery stenting
|
Lin, Chih-Ming; Chang, Yu-Jun; Liu, Chi-Kuang; Yu, Cheng-Sheng; Lu, Henry Horng-Shing |
| 亞洲大學 |
2016-11 |
First-ever stroke following hip replacement surgeries: a large population-based survey.
|
Wang, Chia-To;Wang, Chia-To;Chuang, Eric;Chuang, Eric;Yen, Der-Jen;Yen, Der-Jen;Chu, Tien-Yow;Chuang, Tien-Yow;Mu, Chih-Hsin;Muo, Chih-Hsin;高嘉鴻;Kao, Chia-Hung;* |
| 淡江大學 |
2012-07-06 |
First-fit chromatic numbers of d-degenerate graphs
|
Chang, Gerard Jennhwa;Hsu, Hsiang-Chun |
| 國立臺灣大學 |
2012 |
First-generation college students' information seeking: Their personality traits and source use behavior in coursework-related context
|
TIEN-I TSAI; Tsai, T.-I. and Kim, K.-S. |
| 國立高雄師範大學 |
1998 |
First-grade children’s use of analogy in word reading
|
C. C. Wang;J. S. Gaffney |
| 國家衛生研究院 |
2021-08-12 |
First-in-Asian double-blind randomized trial to assess the efficacy and safety of insulin sensitizer in nonalcoholic steatohepatitis patients
|
Huang, JF;Dai, CY;Huang, CF;Tsai, PC;Yeh, ML;Hsu, PY;Huang, SF;Bair, MJ;Hou, NJ;Huang, CI;Liang, PC;Lin, YH;Wang, CW;Hsieh, MY;Chen, SC;Lin, ZY;Yu, ML;Chuang, WL |
| 國家衛生研究院 |
2024-01-29 |
First-in-class dual EZH2-HSP90 inhibitor eliciting striking antiglioblastoma activity in vitro and in vivo
|
Sharma, S;Wang, SA;Yang, WB;Lin, HY;Lai, MJ;Chen, HC;Kao, TY;Hsu, FL;Nepali, K;Hsu, TI;Liou, JP |
| 臺大學術典藏 |
2021-07-21T23:21:30Z |
First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma
|
Italiano, Antoine; Cassier, Philippe A.; Chia-Chi Lin; Alanko, Tuomo; Peltola, Katriina J.; Gazzah, Anas; Shiah, Her Shyong; Calvo, Emiliano; Cervantes, Andrés; Roda, Desamparados; Tosi, Diego; Gao, Bo; Millward, Michael; Warburton, Lydia; Tanner, Minna; Englert, Stefan; Lambert, Stacie; Parikh, Apurvasena; Afar, Daniel E.; Vosganian, Gregory; Moreno, Victor |
| 臺大學術典藏 |
2022-09-15T01:08:44Z |
First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma
|
Italiano A.; Cassier P.A.; Chia-Chi Lin; Alanko T.; Peltola K.J.; Gazzah A.; Shiah H.-S.; Calvo E.; Cervantes A.; Roda D.; Tosi D.; Gao B.; Millward M.; Warburton L.; Tanner M.; Englert S.; Lambert S.; Parikh A.; Afar D.E.; Vosganian G.; Moreno V. |
| 國立臺灣大學 |
2015 |
First-in-human phase I study of EGF816, a third generation, mutant-selective EGFR tyrosine kinase inhibitor, in advanced non-small cell lung cancer (NSCLC) harboring T790M.
|
Tan, Daniel Shao-Weng; Seto, Takashi; Leighl, Natasha B.; Riely, Gregory J.; Sequist, Lecia V.; Felip, Enriqueta; Wolf, Juergen; Yang, James Chih-Hsin; Matushansky, Igor; Yu, Xiaolu; Schmitz, Shu-Fang Hsu; Cui, Xiaoming; Kim, Dong-Wan; 楊志新 |
| 臺大學術典藏 |
2021-08-11T03:46:35Z |
First-in-human phase i study of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma
|
Kim R.D.; Sarker D.; Meyer T.; Yau T.; Macarulla T.; Park J.-W.; Choo S.P.; Hollebecque A.; Sung M.W.; Lim H.-Y.; Mazzaferro V.; Trojan J.; Zhu A.X.; Yoon J.-H.; Sharma S.; ZHONG-ZHE LIN; Chan S.L.; Faivre S.; Feun L.G.; Yen C.-J.; Dufour J.-F.; Palmer D.H.; Llovet J.M.; Manoogian M.; Tugnait M.; Stransky N.; Hagel M.; Kohl N.E.; Lengauer C.; Sherwin C.A.; Schmidt-Kittler O.; Hoeflich K.P.; Shi H.; Wolf B.B.; Kang Y.-K. |
| 臺大學術典藏 |
2022-06-10T06:10:56Z |
First-in-human phase i study of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma
|
Kim R.D.; Sarker D.; Meyer T.; Yau T.; Macarulla T.; Park J.-W.; Choo S.P.; Hollebecque A.; Sung M.W.; Lim H.-Y.; Mazzaferro V.; Trojan J.; Zhu A.X.; Yoon J.-H.; Sharma S.; ZHONG-ZHE LIN; Chan S.L.; Faivre S.; Feun L.G.; Yen C.-J.; Dufour J.-F.; Palmer D.H.; Llovet J.M.; Manoogian M.; Tugnait M.; Stransky N.; Hagel M.; Kohl N.E.; Lengauer C.; Sherwin C.A.; Schmidt-Kittler O.; Hoeflich K.P.; Shi H.; Wolf B.B.; Kang Y.-K. |
| 國立成功大學 |
2019 |
First-in-human phase i study of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma
|
Kim, R.D.;Sarker, D.;Meyer, T.;Yau, T.;Macarulla, T.;Park, J.-W.;Choo, S.P.;Hollebecque, A.;Sung, M.W.;Lim, H.-Y.;Mazzaferro, V.;Trojan, J.;Zhu, A.X.;Yoon, J.-H.;Sharma, Sharma S.;Lin, Z.-Z.;Chan, S.L.;Faivre, S.;Feun, L.G.;Yen, C.-J.;Dufour, J.-F.;Palmer, D.H.;Llovet, J.M.;Manoogian, Manoogian M.;Tugnait, M.;Stransky, N.;Hagel, M.;Kohl, N.E.;Lengauer, C.;Sherwin, C.A.;Schmidt-Kittler, O.;Hoeflich, K.P.;Shi, H.;Wolf, B.B.;Kang, Y.-K. |
| 中山醫學大學 |
2020 |
First-in-Human study of JNJ-55920839 in healthy volunteers and patients with systemic lupus erythematosus: a randomised placebo-controlled phase 1 trial
|
Jordan, J; Benson, J; Chatham, WW; Furie, RA; Stohl, W; Wei, JCC; Marciniak, S; Yao, ZL; Srivastava, B; Schreiter, J; Cesaroni, M; Orillion, A; Seridi, L; Chevrier, M |
| 臺大學術典藏 |
2020-05-26T09:26:20Z |
First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trials
|
Schuler M;Paz-Ares L;Sequist L.V;Hirsh V;Lee K.H;Wu Y.-L;Lu S;Zhou C;Feng J;Ellis S.H;Samuelsen C.H;Tang W;M?rten A;Ehrnrooth E;Park K;Chih-Hsin Yang; Schuler M; Paz-Ares L; Sequist L.V; Hirsh V; Lee K.H; Wu Y.-L; Lu S; Zhou C; Feng J; Ellis S.H; Samuelsen C.H; Tang W; Märten A; Ehrnrooth E; Park K; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:26:22Z |
First-line afatinib for the treatment of EGFR mutation-positive non-small-cell lung cancer in the ?�real-world??clinical setting
|
Park K;Wan-Teck Lim D;Okamoto I;Chih-Hsin Yang; Park K; Wan-Teck Lim D; Okamoto I; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:26:48Z |
First-line afatinib versus chemotherapy in patients with non-small cell lung cancer and common epidermal growth factor receptor gene mutations and brain metastases
|
Chih-Hsin Yang;Zazulina V;Massey D;Sequist L.V;Popat S;Mok T;Yamamoto N;O'Byrne K;Hirsh V;Wu Y.-L;Schuler M; Schuler M; Wu Y.-L; Hirsh V; O'Byrne K; Yamamoto N; Mok T; Popat S; Sequist L.V; Massey D; Zazulina V; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:26:20Z |
First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression
|
Schuler M;Tan E.-H;O??Byrne K;Zhang L;Boyer M;Mok T;Hirsh V;Chih-Hsin Yang;Lee K.H;Lu S;Shi Y;Kim S.-W;Laskin J;Kim D.-W;Arvis C.D;K?lbeck K;Massey D;M?rten A;Paz-Ares L;Park K.; Schuler M; Tan E.-H; O?�Byrne K; Zhang L; Boyer M; Mok T; Hirsh V; CHIH-HSIN YANG; Lee K.H; Lu S; Shi Y; Kim S.-W; Laskin J; Kim D.-W; Arvis C.D; Kölbeck K; Massey D; Märten A; Paz-Ares L; Park K. |
| 臺大學術典藏 |
2022-05-10T08:09:28Z |
First-line anaplastic lymphoma kinase (Alk) inhibitors for alk-positive lung cancer in asian populations: Systematic review and network meta-analysis
|
Wu K.-L.; Chen H.-L.; Tsai Y.-M.; Lee T.-H.; Chang H.-M.; Tsai Y.-C.; Chuang C.-H.; Chang Y.-C.; YU-KANG TU; Yang C.-J.; Hung J.-Y.; Chong I.-W. |
| 國家衛生研究院 |
2017-10 |
First-line antibiotic therapy in Helicobacter pylori-negative low-grade gastric mucosa-associated lymphoid tissue lymphoma
|
Kuo, SH;Yeh, KH;Wu, MS;Lin, CW;Wei, MF;Liou, JM;Wang, HP;Chen, LT;Cheng, AL |
| 臺大學術典藏 |
2018-09-10T18:04:32Z |
First-line antibiotic therapy in Helicobacter pylori-negative low-grade gastric mucosa-associated lymphoid tissue lymphoma
|
Kuo, S.-H. and Yeh, K.-H. and Wu, M.-S. and Lin, C.-W. and Wei, M.-F. and Liou, J.-M. and Wang, H.-P. and Chen, L.-T. and Cheng, A.-L.; JYH-MING LIOU; CHUNG-WU LIN; MING-SHIANG WU; ANN-LII CHENG |
| 臺大學術典藏 |
2020-03-03T03:36:41Z |
First-line antibiotic therapy in Helicobacter pylori-negative low-grade gastric mucosa-associated lymphoid tissue lymphoma
|
Kuo S.-H.;Yeh K.-H.;Wu M.-S.;Chung-Wu Lin;Wei M.-F.;Liou J.-M.;Wang H.-P.;Chen L.-T.;Cheng A.-L.; Kuo S.-H.; Yeh K.-H.; Wu M.-S.; CHUNG-WU LIN; Wei M.-F.; Liou J.-M.; Wang H.-P.; Chen L.-T.; Cheng A.-L. |
| 臺大學術典藏 |
2020-11-02T02:04:20Z |
First-line antibiotic therapy in Helicobacter pylori-negative low-grade gastric mucosa-associated lymphoid tissue lymphoma
|
Cheng A.-L.; Chen L.-T.; Wang H.-P.; Liou J.-M.; Wei M.-F.; Lin C.-W.; MING-SHIANG WU; Yeh K.-H.; Kuo S.-H. |
| 臺大學術典藏 |
2021-02-02T02:21:00Z |
First-line antibiotic therapy in Helicobacter pylori-negative low-grade gastric mucosa-associated lymphoid tissue lymphoma
|
Kuo S.-H.; Yeh K.-H.; MING-SHIANG WU; Lin C.-W.; Wei M.-F.; Liou J.-M.; Wang H.-P.; Chen L.-T.; Cheng A.-L. |
| 臺大學術典藏 |
2021-02-23T08:26:17Z |
First-line antibiotic therapy in Helicobacter pylori-negative low-grade gastric mucosa-associated lymphoid tissue lymphoma
|
Sung-Hsin Kuo;Yeh K.-H.;Wu M.-S.;Lin C.-W.;Wei M.-F.;Liou J.-M.;Wang H.-P.;Chen L.-T.;Cheng A.-L.; SUNG-HSIN KUO; Yeh K.-H.; Wu M.-S.; Lin C.-W.; Wei M.-F.; Liou J.-M.; Wang H.-P.; Chen L.-T.; Cheng A.-L. |
| 臺大學術典藏 |
2021-08-31T06:29:32Z |
First-line antibiotic therapy in Helicobacter pylori-negative low-grade gastric mucosa-associated lymphoid tissue lymphoma
|
Kuo S.-H.; Yeh K.-H.; Wu M.-S.; Lin C.-W.; Wei M.-F.; Liou J.-M.; Wang H.-P.; Chen L.-T.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-01-15T03:46:33Z |
First-line antibiotic therapy in Helicobacter pylori-negative low-grade gastric mucosa-associated lymphoid tissue lymphoma
|
Kuo S.-H.; Yeh K.-H.; Wu M.-S.; Lin C.-W.; Wei M.-F.; Liou J.-M.; HSIU-PO WANG; Chen L.-T.; Cheng A.-L. |
| 臺大學術典藏 |
2021-01-28T01:06:22Z |
First-line antibiotic therapy in Helicobacter pylori-negative low-grade gastric mucosa-associated lymphoid tissue lymphoma
|
Kuo S.-H.;Kun-Huei Yeh;Wu M.-S.;Lin C.-W.;Wei M.-F.;Liou J.-M.;Wang H.-P.;Chen L.-T.;Cheng A.-L.; Kuo S.-H.; KUN-HUEI YEH; Wu M.-S.; Lin C.-W.; Wei M.-F.; Liou J.-M.; Wang H.-P.; Chen L.-T.; Cheng A.-L. |
| 臺大學術典藏 |
2021-05-27T08:20:46Z |
First-line antibiotic therapy in Helicobacter pylori-negative low-grade gastric mucosa-associated lymphoid tissue lymphoma
|
Kuo S.-H.; Yeh K.-H.; Wu M.-S.; Lin C.-W.; Wei M.-F.; JYH-MING LIOU; Wang H.-P.; Chen L.-T.; Cheng A.-L. |
| 國立成功大學 |
2017 |
First-line antibiotic therapy in Helicobacter pylori-negative low-grade gastric mucosa-associated lymphoid tissue lymphoma
|
Kuo, S.-H.;Yeh, K.-H.;Wu, M.-S.;Lin, C.-W.;Wei, M.-F.;Liou, J.-M.;Wang, H.-P.;Chen, L.-T.;Cheng, A.-L. |
| 臺大學術典藏 |
2020-08-12T06:34:32Z |
First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study
|
Geater S.L.; Wolf J.; Paz-Ares L.; Soria J.-C.; Tan D.S.W.; Chiari R.; Wu Y.-L.; Soria J.-C.;Tan D.S.W.;Chiari R.;Wu Y.-L.;Paz-Ares L.;Wolf J.;Geater S.L.;Orlov S.;Cortinovis D.;Chong-Jen Yu;Hochmair M.;Cortot A.B.;Tsai C.-M.;Moro-Sibilot D.;Campelo R.G.;Mcculloch T.;Sen P.;Dugan M.;Pantano S.;Branle F.;Massacesi C.;De Castro G.;Jr; Orlov S.; Cortinovis D.; CHONG-JEN YU; Hochmair M.; Cortot A.B.; Tsai C.-M.; Moro-Sibilot D.; Campelo R.G.; McCulloch T.; Sen P.; Dugan M.; Pantano S.; Branle F.; Massacesi C.; de Castro G.; Jr |
| 臺大學術典藏 |
2022-06-27T07:00:11Z |
First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study
|
Soria J.-C.; Tan D.S.W.; Chiari R.; Wu Y.-L.; Paz-Ares L.; Wolf J.; Geater S.L.; Orlov S.; Cortinovis D.; CHONG-JEN YU; Hochmair M.; Cortot A.B.; Tsai C.-M.; Moro-Sibilot D.; Campelo R.G.; McCulloch T.; Sen P.; Dugan M.; Pantano S.; Branle F.; Massacesi C.; de Castro G.; Jr |
| 國立臺灣大學 |
2014 |
First-line Combination Therapy with Rituximab and Corticosteroids is Effective and Safe for Pemphigus
|
Cho, Yung-Tsu; Lee, Fang-Yu; Chu, Chia-Yu; Wang, Li-Fang |
| 臺大學術典藏 |
2019-12-04T08:43:43Z |
First-line combination therapy with rituximab and corticosteroids is effective and safe for pemphigus
|
Cho Y.-T.;Lee F.-Y.;Chia-Yu Chu;Wang L.-F.; Cho Y.-T.; Lee F.-Y.; CHIA-YU CHU; Wang L.-F. |
| 國立臺灣大學 |
2015 |
First-line combination therapy with rituximab and corticosteroids provides a high complete remission rate in moderate-to-severe bullous pemphigoid
|
Cho, Y. T.; Chu, C. Y.; Wang, L. F.; 王莉芳 |
| 臺大學術典藏 |
2015 |
First-line combination therapy with rituximab and corticosteroids provides a high complete remission rate in moderate-to-severe bullous pemphigoid
|
Cho, Y.T.;Chu, C.Y.;Wang, L.F.; LI-FANG WANG; CHIA-YU CHU |
| 臺大學術典藏 |
2019-12-04T08:43:40Z |
First-line combination therapy with rituximab and corticosteroids provides a high complete remission rate in moderate-to-severe bullous pemphigoid
|
Wang L.F.; Cho Y.T.; CHIA-YU CHU; Cho Y.T.;Chia-Yu Chu;Wang L.F. |
| 國立成功大學 |
2016-08 |
First-Line Disease Modifying Therapies in Preventing Multiple Sclerosis Relapse - A Nationwide Observational Study in Taiwan
|
Chou, Chih-Ho; Lin, Tzu-Chieh; Cheng, Ching-Lan; Yang, Yea-Huei Kao |
| 臺大學術典藏 |
2022-06-27T07:00:23Z |
First-line erlotinib therapy until and beyond response evaluation criteria in solid tumors progression in Asian patients with epidermal growth factor receptor mutation-positive non-small-cell lung cancer the ASPIRATION study
|
Park K.; CHONG-JEN YU; Kim S.-W.; Lin M.-C.; Sriuranpong V.; Tsai C.-M.; Lee J.-S.; Kang J.-H.; Chan K.C.A.; Perez-Moreno P.; Button P.; Ahn M.-J.; Mok T. |
| 國家衛生研究院 |
2018-01 |
First-line Helicobacter pylori eradication therapies in countries with high and low clarithromycin resistance: A systematic review and network meta-analysis
|
Yeo, YH;Shiu, SI;Ho, HJ;Zou, B;Lin, JT;Wu, MS;Liou, JM;Wu, CY;Consortium, Taiwan Gastrointestinal Disease and Helicobacter |
| 臺大學術典藏 |
2018-09-10T18:04:31Z |
First-line Helicobacter pylori eradication therapies in countries with high and low clarithromycin resistance: a systematic review and network meta-analysis
|
Yeo, Y.H. and Shiu, S.-I. and Ho, H.J. and Zou, B. and Lin, J.-T. and Wu, M.-S. and Liou, J.-M. and Wu, C.-Y.; JYH-MING LIOU; MING-SHIANG WU |
| 臺大學術典藏 |
2020-11-02T02:04:18Z |
First-line Helicobacter pylori eradication therapies in countries with high and low clarithromycin resistance: A systematic review and network meta-analysis
|
Wu C.-Y.; Liou J.-M.; MING-SHIANG WU; Lin J.-T.; Zou B.; Ho H.J.; Shiu S.-I.; Yeo Y.H. |
| 臺大學術典藏 |
2021-02-02T02:20:59Z |
First-line Helicobacter pylori eradication therapies in countries with high and low clarithromycin resistance: A systematic review and network meta-analysis
|
Yeo Y.H.; Shiu S.-I.; Ho H.J.; Zou B.; Lin J.-T.; MING-SHIANG WU; Liou J.-M.; Wu C.-Y. |
| 臺大學術典藏 |
2021-05-27T08:20:46Z |
First-line Helicobacter pylori eradication therapies in countries with high and low clarithromycin resistance: A systematic review and network meta-analysis
|
Yeo Y.H.; Shiu S.-I.; Ho H.J.; Zou B.; Lin J.-T.; Wu M.-S.; JYH-MING LIOU; Wu C.-Y. |
